Horny Goat Weed Capsules Recalled for Undeclared Sildenafil
To the Moon Capsules are being recalled nationwide because they contain undeclared sildenafil, a prescription pharmaceutical. The product was marketed without FDA approval.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: FDA Class I classification applies. Although no illnesses or injuries have been reported, undeclared sildenafil presents serious potential for drug interactions and cardiovascular effects, particularly in consumers taking other medications.
Plain-English summary
Integrity Products is recalling To the Moon Capsules (Horny Goat Weed, 1000 mg) because the product contains undeclared sildenafil, a prescription drug ingredient. The product was marketed without an FDA-approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA).
The affected product with lot HGW221116 (Batch 022123-1, expiration date 5/31/2025) was distributed nationwide across the United States, affecting 2,500 boxes.
Consumers who have purchased this product should stop using it immediately. Sildenafil is a prescription medication with potential for serious drug interactions and cardiovascular effects. For more information, consumers can contact Integrity Products at 1710 Fenpark Dr., Fenton, MO 63026.
The recalled product
- Product
- To the Moon Capsules, Horny Goat Weed, 1000 mg, packaged in a box containing a 10-count blister card, Distributed By: Integrity Products, 1710 Fenpark Dr., Fenton, MO 63026
- Manufacturer
- Integrity Products
- Category
- Drug — Dietary Supplement
- Hazard
- undeclared-sildenafil
- drug-interaction-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot HGW221116 (Batch 022123-1)
- Exp 5/31/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27